Moderna, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +65

Moderna (MRNA) Stock Rallies on Nasdaq-100 Inclusion News

Analyst downgrade Company update AI-generated analysis

πŸ“ˆ Moderna shares climbed 2.2% in pre-market trading to $193.15 following confirmation of its inclusion in the Nasdaq-100 Index before markets open on October 9.

πŸ”„ The index rebalancing replaces Warner Bros. Discovery, triggering mandatory buying from over $800 billion in assets tied to the benchmark index.

πŸš€ Moderna stock has surged approximately 553% since January, reaching a market value near $75.4 billion driven by positive Phase 3 results for its melanoma vaccine intismeran autogene.

πŸ“‰ Citi analyst Geoff Meacham downgraded Moderna to Sell from Neutral, arguing the current price near $200 requires nearly $13 billion in yearly oncology sales to justify.

🀝 The company's positive stock performance is largely attributed to a 222% gain since reporting interim results for its personalized melanoma vaccine developed alongside Merck.

πŸ‘” Moderna appointed Juan Andres as the new Chief Operating Officer to help scale manufacturing operations as its oncology pipeline expands.

πŸ“Š Wall Street consensus remains split with an average price target of $110.44, which is 42% below the current trading price.

πŸ—“οΈ Investors are anticipating new data presentation at the ESMO conference on October 24, which could act as a future catalyst for the stock.

Bullish Signals
  • Moderna shares rallied 2.2% in pre-market trading to $193.15 following its official inclusion in the Nasdaq-100 Index effective October 9.
  • The index rebalancing creates significant buying pressure as funds tracking the $800 billion Nasdaq-100 must purchase shares to maintain their benchmark allocations.
  • Moderna stock has gained approximately 553% since January, reaching a market value near $75.4 billion in an extraordinary year for the company.
  • Positive Phase 3 interim results for intismeran autogene, a personalized melanoma vaccine developed with Merck, drove a roughly 222% gain in shares since those reports were released.
  • The stock is currently trading close to its 52-week high of $208.90, marking a dramatic turnaround from years of decline after the pandemic-era vaccine boom faded.
Risk Factors
  • Citi analyst Geoff Meacham downgraded Moderna to Sell from Neutral, stating that the current share price near $200 implies nearly $13 billion in yearly oncology sales.
  • Analysts view the implied sales expectations required to justify the current valuation as unrealistic given the firm's current forecasts for its cancer business.
  • The average Wall Street price target sits at $110.44, which is 42% below where the stock currently trades, indicating a wide divergence in opinion among analysts.
Full Analysis
Moderna (MRNA) shares rallied 2.2% in pre-market trading on Friday, reaching $193.15, driven by the company's inclusion in the Nasdaq-100 Index effective October 9. This index rebalancing replaces Warner Bros. Discovery, which is being absorbed into Paramount Skydance following a judge-approved settlement expected to close on October 6. The shift triggers mandatory buying from funds tracking the $800 billion index, creating significant upward pressure on Moderna's stock price. The rally reflects an extraordinary year for the biotech firm, with shares surging approximately 553% since January to a market value near $75.4 billion. Much of this momentum stems from positive Phase 3 interim results for intismeran autogene, a personalized melanoma vaccine developed in partnership with Merck, which drove a roughly 222% gain since those reports. Moderna is currently trading close to its 52-week high of $208.90, marking a dramatic recovery from years of decline following the pandemic-era vaccine boom. Despite the bullish market reaction, analyst sentiment remains divided regarding the stock's valuation. Citi analyst Geoff Meacham downgraded Moderna to Sell from Neutral, citing unrealistic sales expectations required to justify the current price near $200. While the average Wall Street price target sits at $110.44, representing a 42% discount to current levels, investors are now awaiting new data presentation at the ESMO conference on October 24, which could serve as the next major catalyst for the stock.